Walgreens Boots Alliance (WBA - Free Report) reported $36.71 billion in revenue for the quarter ended November 2023, representing a year-over-year increase of 10%. EPS of $0.66 for the same period compares to $1.16 a year ago.
The reported revenue represents a surprise of +5.10% over the Zacks Consensus Estimate of $34.92 billion. With the consensus EPS estimate being $0.63, the EPS surprise was +4.76%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Walgreens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Number of locations at period end: 8,631 versus the two-analyst average estimate of 8,684.
- Comparable sales - U.S. Retail Pharmacy - Pharmacy: 13.1% versus 0.4% estimated by two analysts on average.
- Revenues- U.S. Healthcare: $1.93 billion versus $2.03 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +95.3% change.
- Revenues- International: $5.83 billion compared to the $5.38 billion average estimate based on five analysts. The reported number represents a change of +12.4% year over year.
- Revenues- U.S. Retail Pharmacy: $28.94 billion versus $27.44 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6.4% change.
- Revenues- U.S. Retail Pharmacy- Retail: $6.56 billion versus the three-analyst average estimate of $6.95 billion.
- Revenues- U.S. Retail Pharmacy- Pharmacy: $22.38 billion versus the three-analyst average estimate of $20.61 billion.
- Revenues- International - Wholesale: $2.97 billion compared to the $2.72 billion average estimate based on two analysts.
- Revenues- International - Pharmacy: $926 million versus $885.42 million estimated by two analysts on average.
- Revenues- International - Retail: $1.93 billion compared to the $1.73 billion average estimate based on two analysts.
- Adjusted operating income (loss)- U.S. Retail Pharmacy: $694 million compared to the $644.18 million average estimate based on three analysts.
- Adjusted operating income (loss)- U.S. Healthcare: -$96 million versus the three-analyst average estimate of -$87.85 million.
View all Key Company Metrics for Walgreens here>>>Shares of Walgreens have returned +19.6% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Walgreens Boots Alliance (WBA - Free Report) reported $36.71 billion in revenue for the quarter ended November 2023, representing a year-over-year increase of 10%. EPS of $0.66 for the same period compares to $1.16 a year ago.
The reported revenue represents a surprise of +5.10% over the Zacks Consensus Estimate of $34.92 billion. With the consensus EPS estimate being $0.63, the EPS surprise was +4.76%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Walgreens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Number of locations at period end: 8,631 versus the two-analyst average estimate of 8,684.
- Comparable sales - U.S. Retail Pharmacy - Pharmacy: 13.1% versus 0.4% estimated by two analysts on average.
- Revenues- U.S. Healthcare: $1.93 billion versus $2.03 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +95.3% change.
- Revenues- International: $5.83 billion compared to the $5.38 billion average estimate based on five analysts. The reported number represents a change of +12.4% year over year.
- Revenues- U.S. Retail Pharmacy: $28.94 billion versus $27.44 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6.4% change.
- Revenues- U.S. Retail Pharmacy- Retail: $6.56 billion versus the three-analyst average estimate of $6.95 billion.
- Revenues- U.S. Retail Pharmacy- Pharmacy: $22.38 billion versus the three-analyst average estimate of $20.61 billion.
- Revenues- International - Wholesale: $2.97 billion compared to the $2.72 billion average estimate based on two analysts.
- Revenues- International - Pharmacy: $926 million versus $885.42 million estimated by two analysts on average.
- Revenues- International - Retail: $1.93 billion compared to the $1.73 billion average estimate based on two analysts.
- Adjusted operating income (loss)- U.S. Retail Pharmacy: $694 million compared to the $644.18 million average estimate based on three analysts.
- Adjusted operating income (loss)- U.S. Healthcare: -$96 million versus the three-analyst average estimate of -$87.85 million.
View all Key Company Metrics for Walgreens here>>>Shares of Walgreens have returned +19.6% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Get the latest research report on WBA - FREE